Core Viewpoint - Aoxing Life Science Technology (06118.HK) reported a decrease in revenue for the first half of 2025, but significant growth in net profit and order intake, indicating resilience in key projects and operational efficiency [1] Financial Performance - Revenue for the first half of 2025 was RMB 662 million, a decrease of 5.57% year-on-year [1] - Profit attributable to owners increased to RMB 24.999 million, a year-on-year growth of 325.37% [1] - Basic earnings per share were RMB 0.05 [1] Order and Project Performance - Total order amount for the first half of 2025 was approximately RMB 1.0418 billion, an increase of about RMB 135.7 million or 15.0% year-on-year [1] - The integrated process and packaging equipment systems business saw a significant growth of 32.3% [1] - Consulting, digitalization, and construction business segments also experienced a growth of 4.2% [1] Cash Flow and Profitability - Net profit after tax showed a significant increase compared to the same period in 2024 [1] - Operating cash flow increased by over 99% compared to 2024 [1]
奥星生命科技(06118.HK)上半年纯利增长325.37%至2499.9万元 订单承接量同比增长15.0%